[Ischemia tolerance; model for research, hope for clinical practice?]

Area of Science:

• Neuroscience
• Molecular Biology
• Pathophysiology

Context:

• Cerebral ischemia, a leading cause of disability, presents significant therapeutic challenges.
• Experimental models demonstrate that a brief ischemic event confers resistance to subsequent, longer ischemic insults, a phenomenon known as ischemic tolerance.
• This protective effect is observed in both global and focal cerebral ischemia, significantly reducing neuronal damage and infarct volume.

Purpose:

• To elucidate the largely unknown molecular mechanisms underlying ischemic tolerance in the brain.
• To identify the key molecular players and signaling pathways involved in both the early and delayed phases of ischemic tolerance.
• To explore the potential clinical relevance of ischemic tolerance, drawing parallels with preconditioning phenomena in other organs.

Summary:

• Ischemic tolerance involves specific molecular pathways during induction, including N-methyl-d-aspartate (NMDA) and adenosine receptors, and potentially oxygen free radicals and energy metabolism conservation.
• Signal transduction to achieve tolerance involves protein kinases, transcription factors, and immediate early genes.
• Early-phase tolerance (hours) involves adenosine receptors and ATP-dependent potassium channels, while delayed protection (days) is linked to genetic remodeling with altered gene expression (e.g., heat-shock proteins, cytokines, antioxidant enzymes).

Impact:

• Understanding ischemic tolerance mechanisms can lead to novel therapeutic strategies for stroke prevention and treatment.
• Identifying preconditioning-like effects in clinical settings, such as transient ischemic attacks (TIAs) before stroke, could improve patient outcomes.
• This research lays the groundwork for developing interventions that mimic ischemic preconditioning to protect brain tissue from ischemic damage.